| The production of polyhydroxyalkanoates in recombinant Escherichia coli R Li, H Zhang, Q Qi Bioresource technology 98 (12), 2313-2320, 2007 | 209 | 2007 |
| Prediction of pharmacokinetics and drug–drug interactions when hepatic transporters are involved R Li, HA Barton, MV Varma Clinical pharmacokinetics 53 (8), 659-678, 2014 | 97 | 2014 |
| A novel-designed Escherichia coli for the production of various polyhydroxyalkanoates from inexpensive substrate mixture R Li, Q Chen, PG Wang, Q Qi Applied microbiology and biotechnology 75, 1103-1109, 2007 | 87 | 2007 |
| A “middle-out” approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling R Li, HA Barton, PD Yates, A Ghosh, AC Wolford, KA Riccardi, TS Maurer Journal of pharmacokinetics and pharmacodynamics 41, 197-209, 2014 | 72 | 2014 |
| Soluble electron shuttles can mediate energy taxis toward insoluble electron acceptors R Li, JM Tiedje, C Chiu, RM Worden Environmental science & technology 46 (5), 2813-2820, 2012 | 63 | 2012 |
| Comparison of species and cell-type differences in fraction unbound of liver tissues, hepatocytes, and cell lines K Riccardi, S Ryu, J Lin, P Yates, D Tess, R Li, D Singh, BR Holder, ... Drug Metabolism and Disposition 46 (4), 415-421, 2018 | 43 | 2018 |
| Hepatic Disposition of Gemfibrozil and Its Major Metabolite Gemfibrozil 1-O-β-Glucuronide E Kimoto, R Li, RJ Scialis, Y Lai, MVS Varma Molecular pharmaceutics 12 (11), 3943-3952, 2015 | 42 | 2015 |
| A novel unified approach to predict human hepatic clearance for both enzyme-and transporter-mediated mechanisms using suspended human hepatocytes KA Riccardi, DA Tess, J Lin, R Patel, S Ryu, K Atkinson, L Di, R Li Drug Metabolism and Disposition 47 (5), 484-492, 2019 | 41 | 2019 |
| Physiologically based pharmacokinetic prediction of telmisartan in human R Li, A Ghosh, TS Maurer, E Kimoto, HA Barton Drug Metabolism and Disposition 42 (10), 1646-1655, 2014 | 41 | 2014 |
| A mechanistic pharmacokinetic model for liver transporter substrates under liver cirrhosis conditions R Li, HA Barton, TS Maurer CPT: pharmacometrics & systems pharmacology 4 (6), 338-349, 2015 | 35 | 2015 |
| Explaining ethnic variability of transporter substrate pharmacokinetics in healthy Asian and Caucasian subjects with allele frequencies of OATP1B1 and BCRP: a mechanistic … R Li, HA Barton Clinical Pharmacokinetics 57, 491-503, 2018 | 27 | 2018 |
| Permeability comparison between hepatocyte and low efflux MDCKII cell monolayer R Li, YA Bi, Y Lai, K Sugano, SJ Steyn, PE Trapa, L Di The AAPS journal 16, 802-809, 2014 | 25 | 2014 |
| Facilitation of high-rate NADH electrocatalysis using electrochemically activated carbon materials H Li, R Li, RM Worden, SC Barton ACS applied materials & interfaces 6 (9), 6687-6696, 2014 | 22 | 2014 |
| A study on pharmacokinetics of bosentan with systems modeling, part 1: translating systemic plasma concentration to liver exposure in healthy subjects R Li, M Niosi, N Johnson, DA Tess, E Kimoto, J Lin, X Yang, KA Riccardi, ... Drug Metabolism and Disposition 46 (4), 346-356, 2018 | 19 | 2018 |
| Effect of hepatic impairment on OATP1B activity: quantitative pharmacokinetic analysis of endogenous biomarker and substrate drugs J Lin, E Kimoto, S Yamazaki, M Vourvahis, A Bergman, AD Rodrigues, ... Clinical Pharmacology & Therapeutics 113 (5), 1058-1069, 2023 | 16 | 2023 |
| Toward prospective prediction of pharmacokinetics in OATP1B1 genetic variant populations R Li, HA Barton, TS Maurer CPT: Pharmacometrics & Systems Pharmacology 3 (12), 1-9, 2014 | 16 | 2014 |
| Shewanella oneidensis MR-1 Chemotaxis in a Diffusion Gradient Chamber R Li, JM Auchtung, JM Tiedje, RM Worden Environmental science & technology 45 (3), 1014-1020, 2011 | 16 | 2011 |
| Transporter–enzyme interplay and the hepatic drug clearance: what have we learned so far? RV Alluri, R Li, MVS Varma Expert opinion on drug metabolism & toxicology 16 (5), 387-401, 2020 | 15 | 2020 |
| Transporter-mediated disposition, clinical pharmacokinetics and cholestatic potential of glyburide and its primary active metabolites R Li, Y Bi, A Vildhede, RJ Scialis, S Mathialagan, X Yang, LD Marroquin, ... Drug Metabolism and Disposition 45 (7), 737-747, 2017 | 13 | 2017 |
| Comparison of fraction unbound between liver homogenate and hepatocytes at 4 C K Riccardi, S Ryu, D Tess, R Li, L Luo, N Johnson, S Jordan, R Patel, L Di The AAPS Journal 22, 1-9, 2020 | 12 | 2020 |
Manthena V. VarmaPharmacokinetics, dynamics and metabolismBestätigte E-Mail-Adresse bei pfizer.com
